To determine TIME’s annual unranked list, we consider hundreds of inventions from around the world. In the past, we’ve featured everything from the floating lightbulb to the desktop DNA lab. Here, the 25 inventions that made this year’s cut.
Jean George, General Partner, Lightstone Ventures. George has made the Forbes Midas List in the past, but for whatever reason, doesn’t seem like she gets the same credit as others in that club.
KNect 365
Medicare beneficiaries in 23 additional states have been granted reimbursed access to the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure following positive coverage decisions by Medicare Administrative Contractors (MACs) Noridian Health Care Solutions (Noridian) and National Government Services, Inc. (NGS).
EndoGastric Solutions
Data presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), in National Harbor, Maryland-
For most biotech startups, the big challenge lies in developing one or two new drugs that promise to do a better job of targeting a particular disease. But Gemini Therapeutics — the latest in a long lineup of Cambridge, MA biotechs to roll out this year — isn’t like most upstarts.
Endpoints News
Atlas Venture, Lightstone Ventures and OrbiMed have joined up to lead a $42.5 million investment in Gemini Therapeutics.
Fierce Biotech
Celgene has secured an option on two preclinical assets in development at Nimbus Therapeutics. The deal gives Celgene a chance to move into the slipstreams of Bristol-Myers Squibb and Pfizer in the race to bring a TYK2 inhibitor to market.
Fierce Biotech
The company is announcing today a partnership with Celgene, in which the big company is obtaining the option to acquire two different immunology drug programs from Nimbus in preclinical development
Timmerman Report
To develop a high-tech breast pump for the startup Willow, Ideo interviewed dozens of mothers–and uncovered key insights into a problem that the design and technology communities have largely ignored.
Co. Design
Lightstone Ventures, which takes a global approach to health-care venture capital, has raised $250 million for its largest fund aimed at drug and medical-device startups.
WSJ Pro Venture Capital
Global Venture Firm Strengthens Team to Support Growing Portfolio of Early-stage Medical Device and Biopharmaceutical Companies
Nasdaq GlobeNewswire
Disarm Therapeutics, a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, today announced the recent completion of a $30 million Series A financing
Disarm Therapeutics
Lightstone Ventures (LSV) today announced that MediSix Therapeutics Pte Ltd., an early-stage cell therapy company developing novel therapeutics to target T-cell leukemia and lymphoma, has signed an exclusive licensing agreement with the National University of Singapore (NUS).
Nasdaq GlobeNewswire
Existing investors supply Series D funding for clinical trials in rheumatoid arthritis.
Wall Street Journal
Baxter CEO Joe Almeida Isn’t Just a Great Dealmaker, He’s a People Person, Too. When José “Joe” Almeida stepped down as CEO of Covidien after its sale to Medtronic in 2015, he didn’t kick back and rest on his laurels. Before the year was out, he was named chairman and CEO of Baxter International.
Startups targeting lung conditions have raised large financing rounds recently
WSJ Pro Venture Capital
On May 24, a local biotechnology company successfully raised US$33 million (S$44.8 million) through an initial public offering on the Taipei Exchange (TPEx), valuing the company at US$300 million. This went largely unnoticed by most of Singapore, but caused ripples of excitement throughout the local biotech and research circles. The company that listed on the TPEx was none other than a Singapore drug-development biotech, Aslan Pharmaceuticals, which develops therapies for cancer tumour types prevalent in Asia.
The Straits Times
SANTA ROSA, Calif.--(BUSINESS WIRE)--Claret Medical® today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Sentinel™ Cerebral Protection System (CPS), via de novo classification, enabling U.S. commercialization of the device.
Efforts to conquer the growing threat of liver cancer haven’t benefited much from the biotechnology boom.
WSJ Pro Venture Capital
Investors seek strategies for generating maximum value from biotech startups
WSJ Pro Venture Capital
Gilead Sciences has the first proof-of-concept data for its novel drug candidate for nonalcoholic steatohepatitis (NASH) as it tries to rebuild confidence in its R
Fierce Biotech
Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint exploited by cancer cells to evade the immune system, today announced that it has initiated dosing in its Phase 1 clinical program evaluating the safety of ALX148 in patients with advanced solid tumors and lymphoma.
Computational drug discovery firm Nimbus Therapeutics has reached a multiyear partnership with Charles River Laboratories to advance programs across the biotech’s therapeutic areas of expertise.
Fierce Biotech
Investors pump nearly $570 million into treatments for lung cancer, and other serious lung diseases.
Wall Street Journal
California orthopedic device developer Moximed said today it raised $50 million in a Series C round of financing.
Mass Device
Moximed®, Inc., developer of unicompartmental load absorber implants for active patients with painful knee osteoarthritis (OA), announced today an oversubscribed Series C round of $50MM with new investors Advent Life Sciences and Future Fund joining existing investors NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners, and Vertex Healthcare.
Venture capitalists over the years have had their share of complaints about the Food and Drug Administration. Now one of their own is in line to lead the regulatory giant.
WSJ Pro Venture Capital
The primary goal of a hearing instrument is to increase audibility for the impaired listener. However, basic physics limits the performance of air conduction hearing aids in three important ways:
Hearing Review
SANTA ROSA, Calif. – February 27, 2017 – Claret Medical® today announced that in an open public hearing of the FDA’s Circulatory System Devices Panel last week, virtually all panel members recommended the de novo application of the Sentinel® Cerebral Protection System (CPS) be granted, which would enable US commercialization of the device.
Claret Medical
For health-care venture capitalists, the business of improving the body’s appearance has never looked so good.
WSJ Pro Venture Capital
Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research solutions supporting drug discovery and development, announced today a partnership with MolecularMD to combine MolecularMD’s expertise as a provider of molecular diagnostics products and services with Asterand Bio’s drug target and candidate validation capabilities.
After one analyst earlier this month referred to Calithera Biosciences Inc.'s benefit from "pairing promiscuously" with the lead candidate in its pipeline, the company matched efforts in a different way with Incyte Corp. on an early stage prospect, and stands to collect not only $45 million up front and an $8 million equity investment but also as much as $430 million in milestone payments.
Though PowerVision has been around for more than a decade, this past year has been a catalyst for the company’s goal of clearing a path for its innovative fluid-based intraocular lens in what is a crowded market for ophthalmological devices.
Fierce Biotech
Medtech Conference co-chair Stacy Enxing Seng, after succeeding at both start-ups and corporates, shares her enthusiasm for her new role as venture partner at Lightstone Ventures.
The Foundry and Lightstone Ventures (LSV) have partnered to launch Foundry SING1, Inc., a medical technology (medtech) incubator that will identify and address unmet clinical needs in Asia.
Deal Street Asia
ForSight VISION4, a privately held biotechnology company revolutionizing drug delivery for treatment of retinal diseases, announced today that it has been acquired by Roche Holdings Inc.
PR Newswire
Every year thousands of companies, big and small, flock to Las Vegas to unveil their latest gadgets, with every minor spec bump dissected by thousands of journalists in attendance. But at a show filled with tech enthusiasts laser-focused on every new advancement, the most innovative product at the show might just be a smart breast bump called Willow.
Smart breast pumps aren't novel, but a new product relieves moms from the hassle of having to hold up a device or be chained to a power outlet while pumping.
As a new mother, nobody tells you that you'll spend hours of your life sitting on the sofa with a noisy suction monster. No, not your baby -- your breast pump.